Research progress on the pathogenesis of interstitial lung disease induced by Trastuzumab deruxtecan,an antibody-drug conjugate targeting HER2
Trastuzumab deruxtecan(T-DXd)is a new generation of antibody-drug conjugate targeting human epidermal growth factor receptor 2.It has strong antitumor effects and has been recommended by many authoritative guidelines at home and abroad.Drug-induced interstitial lung disease(DILD)is one of the common adverse reactions and causes of death of T-DXd and is an important factor limiting its clinical application.The pathogenesis of DILD induced by T-DXd is still unclear,and the mainstream view holds that it may be related to the non-target-dependent uptake of the drug.Glucocorticoids are an important treatment method for DILD,and other alternative drugs still lack clinical effectiveness evidence.The research progress on the pathogenesis of T-DXd induced DILD was summarized in this review,aiming to provide new ideas for the prevention and treatment of DILD.
国家科技期刊平台
NSTL
万方数据
